De Virgilio Armando, Iocca Oreste, Malvezzi Luca, Di Maio Pasquale, Pellini Raul, Ferreli Fabio, Cugini Giovanni, Colombo Giovanni, Spriano Giuseppe
Otorhinolaryngology Unit, Humanitas University, Humanitas Clinical and Research Center-IRCCS, 20089 Rozzano, Italy.
Otorhinolaryngology Unit, Department of Surgical ad Biomedical Sciences, University of Perugia, Piazza dell'Università, 1, 06123 Perugia, Italy.
J Clin Med. 2019 Feb 18;8(2):256. doi: 10.3390/jcm8020256.
The aim of this systematic review with meta-analysis was to investigate the available literature on transoral approaches in the treatment of hypopharyngeal squamous cell carcinoma, with a special focus on transoral robotic surgery (TORS). A systematic review was conducted according to the PRISMA (preferred reporting items for systematic reviews and meta-analyses) check-list, and 15 studies were included. Five of the included studies evaluated TORS, while ten studies focused on transoral laser microsurgery (TLM) for the treatment of early or advanced stage hypopharyngeal cancer. Overall, survival rates of TLM and TORS studies, analyzed together in the cumulative meta-analysis, were 66.4% (95% confidence interval (CI) 54.3%⁻76.7%) at 36+ months of follow up. The TORS subgroup showed a higher cumulative survival rate (85.5%, 95% CI 55.8%⁻96.5%) compared to TLM (58.5%, 95% CI 46.6%⁻69.6%). Cumulative data showed that 29.3% (95% CI 24.0%⁻35.3%) of deaths were attributable to cancer. The results were similar between TLM and TORS studies. The larynx function preservation cumulative rate was 94.3% (95% CI 91.8%⁻96.1%). The results were similar among the two subgroups. The present review supports the use of transoral approaches in the treatment of hypopharyngeal cancer. TORS is oncologically sound and provides excellent functional results with low complication rates.
本项带有荟萃分析的系统评价旨在调查有关经口入路治疗下咽鳞状细胞癌的现有文献,特别关注经口机器人手术(TORS)。根据PRISMA(系统评价和荟萃分析的首选报告项目)清单进行了系统评价,纳入了15项研究。其中5项纳入研究评估了TORS,而10项研究聚焦于经口激光显微手术(TLM)治疗早期或晚期下咽癌。总体而言,在累计荟萃分析中一起分析的TLM和TORS研究的生存率在随访36个月及以上时为66.4%(95%置信区间(CI)54.3%⁻76.7%)。与TLM(58.5%,95%CI 46.6%⁻69.6%)相比,TORS亚组显示出更高的累积生存率(85.5%,95%CI 55.8%⁻96.5%)。累积数据显示,29.3%(95%CI 24.0%⁻35.3%)的死亡归因于癌症。TLM和TORS研究的结果相似。喉功能保留累积率为94.3%(95%CI 91.8%⁻96.1%)。两个亚组的结果相似。本综述支持经口入路用于治疗下咽癌。TORS在肿瘤学上是合理的,并且能提供出色的功能结果,并发症发生率低。